# Shavit Capital

> Shavit Capital is a VC fund in Jerusalem backing Health Care and Biotechnology. See 7 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Jerusalem, Israel
- Total investments: 7
- Last investment: Jan 2022
- Lead investor: 29%
- Last updated: Aug 2026
- Website: http://www.shavitcapital.com/

Shavit Capital is a VC fund in Jerusalem focused on Health Care and Biotechnology. Shavit Capital Fund is a private equity fund investing primarily in Israeli related companies with a clear path to an IPO (mezzanine rounds) and public companies traded in the US, Israel or other international markets (PIPE/secondary offerings).The Fund seeks investment opportunities in successful, small to medium-sized companies withstrong management teams and demonstrated growth potential

## Contacts

5 contacts available for Shavit Capital. Shizune tracks 4 team members at Shavit Capital. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/shavit-capital?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 3 | 43% |
| Biotechnology | 3 | 43% |
| Medical | 2 | 29% |
| Medical Device | 2 | 29% |
| Content | 1 | 14% |

17 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 1 | 14% |
| Series C | 1 | 14% |
| Series D | 1 | 14% |
| Series E | 1 | 14% |
| Series F | 1 | 14% |

7 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| Israel | 5 | 71% |
| United States | 1 | 14% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Gary Leibler | Managing Director | 1 | https://shizune.co/investors/profile/gary-leibler |
| Leon Recanati | Chairman | 0 | https://shizune.co/investors/profile/leon-recanati |
| Leon Recanati | Co-Founding Partner & Chairman | 7 | https://shizune.co/investors/profile/leon-recanati-glenrock-israel |
| Neil Cohen | Venture Partner | 0 | https://shizune.co/investors/profile/neil-cohen-2 |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| MeMed | MeMed Diagnostics is a personalized diagnostics company founded in 2009. They are here to improve patient care, empower physicians, and lower health-care costs through rapid and actionable diagnostics for infectious diseases. Their main focus is preventing antibiotics misuse.Antibiotics are the most prescribed class of drugs worldwide with aglobal market of 25-30 billion $US. Up to 70% of antibiotics are estimated to be prescribed inappropriately, making them the most misused drug class in the world. Antibiotics misuse leads to ineffective treatment, emergence of resistant strains of bacteria, and is estimated to cost healthcare systems worldwide tens of billions of dollars annually. Their platform, the ImmunoDx™, leverages the world’s most accurate diagnostic system for differentiating bacteria from viruses, crafted by nature, the body’s immune system.ImmunoDx™ combines proprietary biomarkers, algorithms, and clinical know-how to identify the source of infection (virus vs bacteria, bacterial spectrum), by decoding the immune system`s differential response to different pathogens. This unique approach enables ImmunoDx™ to address some of the major challenges facing currently available diagnostics for infectious diseases. | $93M | Series E | Jan 10, 2022 |  |
| Lightricks | Lightricks develops creativity tools that enable its users to craft and share visual content on mobile devices. Lightricks integrates advanced technologies from computer vision, computer graphics, and image processing into mobile products. Lightricks' products include Facetune, Facetune 2, Enlight, Enlight Photofox, Enlight Videoleap, andEnlight Quickshot.Lightricks was founded in January 2013 by five entrepreneurs with comprehensive knowledge in the fields of computer graphics, image processing, machine learning, and artificial intelligence, who left promising careers in order to realize their dream. | $100M | Series D | Sep 19, 2021 |  |
| KAHR medical | KAHR Medical ("KAHR") is pioneering the development of "third generation biological drugs," a unique class of proprietary fusion-protein molecules with clear and far-reaching advantages. KAHR's technology represents a paradigm shift in protein-based pharmaceuticals that will significantly expand available treatment optionsfor cancer and autoimmune disorders. | $46.5M | Venture - Series Unknown | Jun 16, 2021 |  |
| Veev | Veev is a building technology company that reinvents the way homes are built and experienced. Veev's home operating system creates room-specific lighting, shade, and climate control and also offers protection against intrusion and cybercrime, thereby providing clients a one-stop solution to all their smart housing requirements.Key componentsof the Veev panelized building system include the use of light gauge steel (LGS) for framing, high-performance acrylic (HPA) for surfaces and millwork, radiant climate control systems, and a digital home ecosystem. The company is currently focused on high-performance multifamily and accessory dwelling unit (ADU) products. The current development pipeline totals more than 230 units and 620,000 gross building square feet. | $100M |  | Mar 23, 2021 |  |
| Veev | Veev is a building technology company that reinvents the way homes are built and experienced. Veev's home operating system creates room-specific lighting, shade, and climate control and also offers protection against intrusion and cybercrime, thereby providing clients a one-stop solution to all their smart housing requirements.Key componentsof the Veev panelized building system include the use of light gauge steel (LGS) for framing, high-performance acrylic (HPA) for surfaces and millwork, radiant climate control systems, and a digital home ecosystem. The company is currently focused on high-performance multifamily and accessory dwelling unit (ADU) products. The current development pipeline totals more than 230 units and 620,000 gross building square feet. | $100M | Series C | Mar 23, 2021 |  |
| Alpha Tau Medical | Alpha Tau Medical is an Israeli medical device company that focuses on research, development and commercialization of Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy) for the treatment of solid cancer. The Alpha DaRT technology was developed in 2003 at Tel Aviv University.Since then, numerous preclinical trials have found the technology tobe effective and safe for various indications and anatomic areas.The findings were published in 12 papers in peer-reviewed scientific journals. Today, the company is running its first clinical trial with very promising preliminary results. | $26M | Series B | Jun 04, 2020 |  |
| Gamida Cell | Gamida Cell is dedicated to making a significant difference in the clinical practice of modern medicine by first creating, then tapping the regenerative power of therapeutic stem cells. Gamida Cell is a leader in the development of stem cell therapy technologies and products. The therapies are based on expanded populations of cord blood stem cells,for the treatment of illnesses with significant unmet clinical needs such as blood cancers, autoimmune and metabolic diseases as well as neutropenia. | $40M | Series F | Jun 19, 2017 |  |

7 of 7 investments shown.

## Co-investors
- [Migdal Insurance and Financial Holdings](https://shizune.co/investors/profile/migdal-insurance-and-financial-holdings-ltd) — VC Fund, 3 deals together
- [More Investment House](https://shizune.co/investors/profile/more-investment-house) — VC Fund, 2 deals together
- [Psagot Investment House](https://shizune.co/investors/profile/psagot-investment-house) — VC Fund, 2 deals together
- [Altshuler Shaham](https://shizune.co/investors/profile/altshuler-shaham) — VC Fund, 1 deal together
- [aMoon Fund](https://shizune.co/investors/profile/amoon) — VC Fund, 1 deal together
- [Biotechnology Value Fund](https://shizune.co/investors/profile/biotechnology-value-fund) — VC Fund, 1 deal together

## Similar investors

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

## FAQ

### What does Shavit Capital invest in?

Shavit Capital invests primarily in Health Care, Biotechnology and Medical startups, most often at Series B and Series C stage. Most of the 7 investments tracked by Shizune back companies in Israel. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Shavit Capital?

Public channels for Shavit Capital include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Shavit Capital?

The team at Shavit Capital includes Gary Leibler (Managing Director), Leon Recanati (Chairman) and Leon Recanati (Co-Founding Partner & Chairman). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co